Indivumed Therapeutics
Indivumed Therapeutics is a biotech company focused on precision oncology.
We create novel drug target packages and partner with the pharmaceutical industry to develop precision cancer therapeutics. Within our global network of selected partner clinics, we utilize proprietary protocols and procedures to collect tissue of unmatched quality and variety. By systematically characterizing this tissue at a molecular level and linking it with longitudinal clinical data, we discover novel targets that would otherwise
be undetectable.
Our unique combination of biomathematics, bioinformatics, and cell biology enable us to identify targets and design proof-of-concept drug-screening assays that have a higher chance of success further down the pharmaceutical drug-discovery pipeline.
We envision a world where precision therapy offers a cure for each individual cancer patient
Indivumed at a glance:
| Field of activity | With a data-driven approach to novel target ID, we drive our internal oncology R&D activities and pipeline. Our unique database – containing molecular datasets (genomics, proteomics, transcriptomics, miRNA, and phosphoproteomics) of both normal and tumor tissue and comprehensive longitudinal clinical data – serves as the basis for target discovery programs. |
| Technology | We combine proprietary multi-omics data and multivariate biomathematical analytics to discover novel cancer drug targets. Validation of these targets is performed in patient-derived 2D and 3D cellular tumor models. By adding an extensive biochemical characterization and a proof-of-concept drug screening assay, we create patentable target packages that are further developed in-house or in partnership with pharmaceutical companies. |
| Unique Selling Point | The uniqueness of our approach lies in the quality of the samples and, subsequently, the depth of the molecular data. With our global network of selected partner clinics, we have created unique protocols and procedures to collect tissue samples. Rapid processing, freezing, and fi xing of patient material (in under 12 minutes) preserves the molecular reality of each individual cancer. |
| Membership in Networks/Associations | BIO Deutschland, Life Science Nord e.V. |
| Date of Incorporation/Number of employees | 2022 / 80 |
Contact
| Adress | Falkenried 88, Bldg. D 20251 Hamburg |
| Telephone | +49 40 41 33 83-0 |
| info@indivumed.com | |
| Web Address | www.indivumed.com |
| Social Media |
- Rekordbeteiligung bei den Deutschen Biotechnologietagen 2025 in Heidelberg
- Deutsche Life-Sciences-Branche 2025: Investitionsboom dank innovativer Technologien und starker M&A-Aktivität
- Von Wissenschaft zu Wirtschaft: Biotech-Verband BIO Deutschland fordert Neuerungen für Technologietransfer
- Mehr Jobs und Investitionen in der deutschen Biotechnologie
- Biotech und Life Sciences von Norden bis Süden
- Deutsches Biotech-Fundraising trotzt Herausforderungen
- It's time to focus on cardiovascular diseases!
- Biotechnologieindustrie in Deutschland - die Zeiten ändern sich
- Ruder übergeben: Arbeitsgruppe bei BIO Deutschland unter neuer Führung
- Oliver Schacht wird Geschäftsführer von Life Science Nord
- Von halb leeren und halb vollen Gläsern
- Molecular Health und Integrated DNA Technologies vereinbaren kommerzielle Partnerschaft
- Biosolutions und Biomanufacturing
- 128 Millionen Euro für Tubulis!
- Über 1 Mrd. Euro für deutsche Biotechnologie
- Out now: Circular Bioeconomy 2023
- How to scale up the bioeconomy in Germany
- BioLizard startet neue KI-unterstützte Plattform „BioVerse“
- Biotechnologie-Branchenverband wählt neuen Vorstand
- Myelofibrose: Neue Behandlungsmöglichkeiten für seltenen Blutkrebs in Sicht